Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Novartis, 22 Sep 2010
Accessed on 4 Jan 2012 from http://www.novartis.com/newsroom/media-releases/en/2010/1445917.shtml.